Two Years of Menaquinone-7 Supplementation and Coronary Artery Calcification: A Randomized Clinical Trial

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

To evaluate whether supplementation with the vitamin K homologue menaquinone-7 (MK-7) for a period of 2 years attenuates the progression of coronary artery calcification (CAC) compared with placebo.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

This randomized placebo-controlled clinical trial including symptomatic patients with CAC score between 50 and 400 Agatston units (AU) with 2 years of follow-up (VitaK-CAC study).

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

The study was conducted at 1 university hospital and 1 community-dwelling hospital in the Netherlands.

Data were collected from January 2012 through October 2022 with a few interruptions; analyses were performed from January 2023 to April 2024.

What Was Measured

Topics PubMed links to this paper include Vitamin K 2, Coronary Artery Disease, Vascular Calcification, Dietary Supplements and Disease Progression.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Results are reported in around 15 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (JAMA cardiology), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.